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MR Spectroscopy of Cholesteryl Ester
in Human Atherosclerosis*
John R. Guyton, MDDurham, North CarolinaThe ability to quantify cholesterol and/or cholesteryl
ester deposits in vivo noninvasively, a goal not yet
achieved, could greatly facilitate new discoveries in
atherosclerosis progression and regression. In this
issue of iJACC, Duivenvoorden et al. (1) report
progress in a 1H-magnetic resonance (MR) spec-
troscopic technique that samples an approximate
5-mm cubic voxel in the region of the carotid artery
in humans. Using cholesteryl linoleate and triolein
as representative standards for cholesteryl ester and
triglyceride, respectively, they suggest that the ratio
of cholesteryl ester to triglyceride can be quantiﬁed
and correlated with plaque tissue volume versus
perivascular tissue volume in the voxel of interest.
However, only one-half of the MR spectra obtained
were of adequate quality for analysis.See page 1277Both cholesterol and cholesteryl ester accumulate
pathologically in the arterial intima early in lesion
development (2,3). Cholesterol is the biologically
active molecule. Because cholesterol is rotationally
constrained in lipid membranes and sometimes in
crystals, however, it is nearly undetectable by MR
(4). Cholesteryl ester associates minimally with
membranes and instead forms oil phase lipid
droplets that provide MR spectra but are largely
inert chemically, participating in few reactions
other than hydrolysis of the ester bond to produce
cholesterol. Metabolically, cholesteryl ester repre-
sents a storage or transport form of cholesterol. Cells*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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coenzyme A:cholesterol acyltransferase (ACAT),
which sequesters cholesterol in esteriﬁed form in
lipid droplets and removes the threat of membrane
dysfunction posed by excess cholesterol (5). Scull
and Tabas (6) have suggested that cell death in
atherosclerosis may result in part from overtaxed and
eventually failing cholesterol esteriﬁcation, leading
to apoptosis via cholesterol-driven endoplasmic re-
ticulum stress responses.
Therefore, cholesterol participates in athero-
genesis by mechanisms that are increasingly well
deﬁned. Cholesteryl ester, although not directly
harmful, can be a marker for pathological cholesterol
excess and ACAT activation. Chemically quantiﬁed
cholesteryl ester concentrations in atherosclerotic
lesions can increase to >100-fold higher than in
normal arterial intima (7).
That is not the whole story, however. Cholesteryl
ester in atherosclerotic ﬁbrous plaques may also accu-
mulate directly from plasma lipoproteins without
the intervening steps of cellular uptake, lysosomal
hydrolysis, and ACAT-mediated re-esteriﬁcation.
In plasma lipoproteins, linoleate comprises w45%
of cholesteryl ester fatty acids and oleate 25%, with
the remainder mostly saturated fatty acids. In lesions
rich in foam cells with large lipid droplets, the oleate
fraction increases to 50% and linoleate decreases
to 15%, apparently due to preferential use of oleyl co-
enzyme A by ACAT. However, in the ﬁbrous plaque
core region, the bulk of cholesteryl ester retains a fatty
acyl composition similar to plasma lipoproteins and
resides in small extracellular droplets (7,8). This sug-
gests that most of the cholesteryl ester accumulating
in mature atherosclerotic lesions is not re-esteriﬁed
by ACAT in foam cells, but is derived from an
alternative process of lipoprotein aggregation and
fusion in the extracellular space (9,10).
Duivenvoorden et al. (1) determined the relative
proportion of methylene protons and allylic methylene
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1286protons in the sampled voxel intersecting the carotid
artery wall. Cholesteryl linoleate has 3.6 methylene
protons for each allylic methylene proton, whereas
triolein has a corresponding ratio of 6 to 1. The
detection of atherosclerotic cholesteryl ester is aided
by the fact that it is enriched in linoleate compared
with the intracellular triglyceride in perivascular
tissue, which contains about one-half oleate among
its fatty acids.
MR imaging of lipid deposits in atherosclerotic
lesions in vivo has been performed previously in a
semiquantitative manner, validated by correlations
with histology of excised plaques (11). However,
application to clinical atherosclerosis remains limi-
ted. An impressive initial result was a comparison
between 8 control lipid clinic patients and 8 patients
who had been treated for 10 years with a combined
regimen of lovastatin, niacin, and colestipol. In ca-
rotid plaques of control patients, 17% of plaque
area was ascribed to lipid core, whereas in the
treated patients, only 1% of plaque area appeared
to represent lipid core (12). In a subsequent pro-
spective evaluation of 33 subjects with measurable
lipid-rich necrotic cores at baseline, core volumes
decreased by 38% over 3 years. The 33 subjects arepart of a larger ongoing study of 123 subjects with
coronary artery disease randomized to 3 different
lipid treatment regimens (13).
Niacin, in particular, via activation of the G
protein–coupled receptor GPR109A, has been
shown to augment cholesterol efﬂux in macrophages
(14,15). In mice, niacin inhibited atherogenesis in
a GPR109A-dependent manner (15). Could this
translate into cholesterol removal from human
atherosclerotic lesions? A more direct approach to
cholesterol removal from lesions involves intrave-
nous infusion of reconstituted high-density lipo-
proteins. When this approach was attempted in a
randomized, controlled trial, the limitations of
intravascular ultrasound in deﬁning lesion compo-
nents were sorely apparent (16). Further develop-
ment of the MR spectroscopic procedures described
by Duivenvoorden et al. (1) may eventually allow
these kinds of clinical questions to be addressed
with a new level of precision and speciﬁcity.
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